Plenary thomas hanke


Published on

Presentation of Thomas Hanke PhD, Sourcing Director Novo Nordisk at the plenary program during the Dutch Life Sciences & Health Conference 2010

Published in: Health & Medicine
1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Plenary thomas hanke

  1. 1. Novo Nordisk– your protein partner Thomas Hanke Sourcing Director Novo Nordisk A/S
  2. 2. Novo Nordisk history 1923 1985 1946 1986 1982 1988 1985 1996n NovoPen®, world’s first insulin pen Nordisk insulin NPH Production of NovoPen®, world’sNovoSeven®pen World’s first insulin Recombinant first insulin laboratory founded insulin human insulin in to identical Norditropin® from BHK cells “insulin LEO” yeast human insulin from E. coli
  3. 3. More than 30,000 Novo Nordiskemployees world wide Copenhagen Seattle Zürich Koriyama Princeton Beijing Chatres Tokyo Tianjin Clayton Bangalore Montes ClarosR&D locations Of the more than 30,000 people working in NovoClinical Development centres Nordisk, over 3,500 are in R&DProduction sites Roughly 1,500 of these people are doing research
  4. 4. Novo group structure Novo Seeds Novo Nordisk Foundation Novo Ventures Novo A/S Novo GrowthB-shareholders Equity Novozymes A/S Novo Nordisk A/S B-shareholders Novo Nordisk Novo Nordisk Biotech Fund Affiliates Service Corporate Venture Fund Companies Listed on OMX and NYSE
  5. 5. Increased sales revenue and R&D spend bydouble digits annually over the last 5 years Hormone replacement therapyNovo Nordisk: 2009 6.7 1.4 0,7 9.2 0,4 Growth hormone therapySales by Haemostasis management 2008 5.9 1.3 0.7 8.2therapy area, Diabetes care 0,3USD billion 2007 5.4 1.2 0.6 7.5 +11% 0,3 2006 5.0 1.1 0.5 7.0 0,3 2005 4.1 1.1 0.5 6.0 0,3 2009 1.0 0.5 1.4 BiopharmaceuticalsNovo Nordisk: Diabetes careResearch & 2008 0.8 0.5 1.4Developmentspend, USD +12% 2007 0.9 0.4 1.3billion 2006 0.7 0.4 1.1 2005 0.6 0.3 0.9
  6. 6. Novo Nordisk’s corporate strategyIndications Compounds/Capabilities Strategic focus Insulin• Diabetes Expand leadership Expand leadership GLP-1 Drug delivery and protein expertise Global commercial infrastructure GLP-1• Obesity/pre-diabetes Explore opportunity Other proteins• Haemophilia Coagulation factors• Growth hormone Expand franchise disorders Growth hormone• Menopausal symptoms Hormones Maximise value Proteins / mono-• Inflammation Build presence clonal antibodies
  7. 7. Our strategy is driven by our coreprotein competencies and protein andpeptide R&D focus Mutation Half-life extension Acylation Sustained release Pegylation Liquid Modification Oral delivery • Genetic • Enzymatic • Chemical E.coli Prefilled pens Yeast Durable pensMammalian cells Infusion devices
  8. 8. Novo Nordisk development pipeline This is a Phase 1 placehold er text Phase 2 Phase 3 NN9925 NN9924 Type 2 diabetes Type 2 diabetes NN9068 NN1218 Type 2 diabetes Type 1 and 2 diabetes Semaglutide Liraglutide as anti- Type 2 diabetes obesity agent Obesity NN1952 NN9161 Type 1 and 2 diabetes Obesity Fast-acting rFVIIa analogue Haemophilia with inhibitors DegludecPlus Type 1 and 2 diabetes N8-GP (rFVIII glycopegylated) N7-GP (rFVIIa Haemophilia A Degludec glycopegylated) Haemophilia with inhibitors Type 1 and 2 diabetes Subcutaneous, N7-GP (rFVIIa glycopegylated) rFXIII Haemophilia with inhibitors rFXIII FXIII Congenital deficiency Cardiac surgery N9-GP (rFIX glycopegylated) N8 (rFVIII) Haemophilia B Anti-NKG2D Haemophilia A Inflammation Anti-IL21 Anti-C5aR Anti-IL20 Inflammation Inflammation Inflammation diabetes haemophilia inflammation
  9. 9. Research focus areas across Novo Nordisk World-class research in target discovery and validation, lead identification and optimization Focus disease areas at Novo Nordisk today: • Diabetes • Haemophilia • Obesity • Inflammation Måløv, Gentofte, Beijing, Seattle, DK DK China Wash., USA Protein science and technologies
  10. 10. Diabetes is a growing disease area with continued unmet treatment needs Global disease impact Overweight or obese people in the US with prediabetes, Global burden of … and the epidemic diabetes 2010: diabetes and/or CV risk factors is growing fast From 6.6% today to an ~ 8% by 4 million 2030; Prediabetes Dyslipidemia deaths From 285 to 435 million patients 20M 450 Million people with diabetes 1+ million amputations 400 11M 2M 500,000+ 350 11M 18M 16M 7M 5M kidney 2M 300 failures 13M 250 300,000+ cases 14M 200 of blindness Hypertension Diabetes 150 $376 billion in 2000 2005 2010 2015 2020 2025 2030 global healthcare expenditure Source: NHANES (2007) Estimated Expected prevalence at diabetes time of prevalence in Diabetes Diabetes Atlas Atlas updates Fourth edition, 2009Sources: IDF Diabetes Atlas 2009;Revealing the cost of Type II diabetes in Europe, Z. Jönsson in Diabetologia (2002)
  11. 11. Novo Nordisk is the leader in diabetes care• Global market share leader in diabetes care Total diabetes injectable Market share worldwide• Only company with full range of modern insulins 100%• Leader within insulin delivery systems• Largest number of research projects• Largest private research budget within diabetes Novo Nordisk 43% Sanofi Aventis 30% Eli Lilly 25% Others 1 % 2010
  12. 12. Strongest and most diverse diabetesresearch portfolio in the industryResearch and Research Industry leadingsourcing focus strategies diabetes portfolio Optimized PK/PD Fast acting analoguesInsulin GLP-1 Long acting Increased efficacy analogues Oral Delivery Oral formulations Tailored tissue Combination selectivity treatmentsAnti Functional selective Novel MOA’sobesity Novel anti analogues diabetic drugs
  13. 13. Unmet medical needin haemophiliaIndication Unmet medical need • More than 250,000 severe patients worldwideHaemophilia A • Need for improved dosing convenience and improved adherence to prophylaxis • More than 50,000 severe patients worldwideHaemophilia B • Need for more predictable outcomes in on-demand treatment and improved dosing convenience in prophylaxis, • Need for faster resolution of acute bleedingPatients with and more predictable outcomesinhibitors • Increasing need for safe and effective bleeding prophylaxis
  14. 14. We aim to provide a full portfolioof haemostatic agents Factor 7 Factor 8 Fast-acting rFVIIa analogue Haemophilia with inhibitors N7-GP (rFVIIa glycopegylated) Haemophilia with inhibitors N8 (rFVIII) Haemophilia ASubcutaneous, N7-GP(rFVIIa glycopegylated) NovoSeven N8-GP (rFVIII glycopegylated)Haemophilia with inhibitors Haemophilia with inhibitors Haemophilia A Marketed N9-GP (rFIX glycopegylated) rFXIII Haemophilia B Cardiac surgery Phases rFXIII FXIII Congenital deficiency 3 2 Factor 13 1 Factor 9
  15. 15. Unmet medical need inautoimmune diseasesIndication Unmet medical need • Need for improved efficacyRheumatoid Less than half of patients on biologics achieve clinically relevantArthritis response • Need for improved efficacyPsoriatic Less than half of patients on biologics achieve clinically relevantArthritis responsesInflammatory • Need for improved efficacy and safetyBowel Safe alternatives for TNFα failures needed with fast onset of action,Disease steroid free remission and avoidance of surgerySystemic • Need for improved efficacyLupus Modest efficacy of currently used productsErythematosus
  16. 16. We aim for first-in-class inflammation targets Research AutoimmuneTarget focus capabilities diseases T cells Cytokines Target discovery Rheumatoid arthritis Generating, optimizing and Psoriatic arthritis expressing mAbs In vitro biology Systemic lupus Disease association; analysis of human Crohn’s disease tissue samples In vivo biology; MΦ and DCs animal models Type 1 & 2 diabetes
  17. 17. We have built immunological researchcompetencies Disease association in patient samples: IHC, ISH, Transcript profiling Placeholder T cells MΦ and DCs Animal Cytokines models Treg function Costimulation IBD Structure/ function analysis Th17 function Cytokine secretion RA Signalling Co-culture monocytes Trafficking SLE Transcript profiling Proliferation T1D Target pairing assays
  18. 18. We have a promising pipeline offirst-in-class anti-inflammatory antibodies First-in-class MAb against costimulatory Phase 2 Anti-NKG2D molecule involved in rheumatoid arthritis and Crohn’s disease Fully human MAb against pro- Phase 1 Anti-IL-20 inflammatory cytokine involved in psoriasis and rheumatoid arthritis Humanized MAb against complement Phase 1 Anti-C5aR receptor C5aR involved in rheumatoid arthritis and lupus Fully human MAb against IL-21 Phase 1 Anti-IL-21 for rheumatoid arthritis and other autoimmune diseases
  19. 19. We develop devices for diabetes, growth andhaemostasis therapies
  20. 20. Partnering and licensing are essential parts ofexecuting our strategy….StrategicpartnershipsTechnologypartnershipsDrug targetpartnerships Equity stakes
  21. 21. …and we continuously look fornew partnershipsDiabetes • Novel insulin and GLP-1 peptides and peptidomimetics • Other novel proteins or peptides affecting any aspect of diabetesHaemophilia • Novel non-replacement therapies that improve haemostasisInflammation • Novel and innovative protein and peptide therapies for rheumatoid arthritis, psoriatic arthritis, systemic lupus and Crohn’s diseaseTechnology • Technologies for expressing, modifying or producing proteins and peptides • Formulation and drug delivery technologies for proteins and peptides
  22. 22. We have three interrelated tools Strategic collaborations and licensing Acquisitions Equity investments